REFERENCES
- Deedwania P C. Diabetes and Hypertension, the Deadly Duet: Importance, therapeutic strategy and selection of drug therapy. Cardiol Clin 2005; 23: 137–152.
- Sowers JR, Haffner S. Treatment of C.V. and renal risk factors in the diabetic hypertensive. Hypertension 2002; 40: 781–788.
- Tarnow L, Rossing P et al. Prevalence of arterial hypertension in the diabetic patients before and after JNC-V. Diabetes Care 1994; 17: 1247–1251.
- Gross T W, Nieto FJ et al. Hypertension and antihypertensive therapy as risk factors for T2DM. Aric study. N Engl J Med 2000; 342: 905–912.
- Bakris G L. The importance of Blood Pressure control in the patient with diabetes. Am J Med 2004; 116(Suppl 5A): 30S–38S.
- UKPDS 38. BMJ 1998; 317: 703–713.
- Nilsson P M et al. Update on hypertension management: Treatment of hypertension in patients with T2DM. J Hypertens 2006; 24: 208–210.
- JNC-7: Hypertension 2003; 42: 1206–1252.
- BPLTC: Arch Intern Med 2005; 165: 1410–1419.
- American Diabetes Association. Hypertension management in adults with diabetes. Diabetes Care 2004; 27: Suppl 1: S65–S67.
- Bengtsson C et al. Do antihypertensive drugs precipitate diabetes? BMJ 1984; 289: 1495–1497.
- Opie LH. Old antihypertensives and new diabetes. J Hypertens 2004; 22: 1453–1458.
- Verdeochia P et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension 2004; 43: 963–969.
- Shamiss A et al. Enalapril with and without hydrochlorothiazide: effects on insulin sensitivity and metabolic abnormalities of NIDDM hypertensive patients. Am J Hypertens 1995; 8: 276–281.
- UK Prospective Diabetes Study Group: Effect of Metformin. :Lancet 1998; 352: 854–865.
- Joint British Societies guidelines as prevention of cardiovascular disease in clinical practice. Heart 2005; 91 (Suppl V) 1–52.
- Costa J et al. Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of RCT. Lancet 2006; 332: 1115.